mywealthgrid
Overview
Dashboard
My workspace
My PortfolioWatchlistsFollowingScreenersAlertsResearch
Discover
CompaniesSectorsIndicesMutual fundsInstitutional investorsCompareTrade trends
Market updates
ResultsAnnouncementsSearch filingsCalendarUpcoming listings
Sign in to save your work
Sign inSign up
Loading page…
NF

Ngl Fine-Chem Limited

NSE:NGLFINEBSE:NGLFINE
HealthcarePharmaceuticals & Biotechnology
₹2,924.0
+0.5%1 Oct close
Mkt cap
₹1,813 Cr
Watch Alert Compare
OverviewChartPeersProfit & lossBalance sheetCash flowRatiosShareholdingF&ODocumentsEventsAnnouncementsNotes
AnnualQuarterly
ConsolidatedStandalone

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ CrMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
9596113152151258319275329359489
COGS——-45-63-64103148140155185241
Gross profit—————156170135174174248
777813918419679105107130148187
1818193019776628442660
OPM %18.5%19%16.8%19.8%12.8%29.7%20.6%10.2%13.5%7.2%12.4%
Depreciation——5677888916
Interest1—222221124
015659138161015
Profit before tax1822182814766927512455
Tax685742117612613
Tax %35.7%35.4%29.7%27%26%27%24.3%24.4%24%24.1%23.8%
1214122011555220391842
PAT margin %12.2%14.8%10.9%13.3%7.1%21.5%16.4%7.3%11.7%5.1%8.5%
EPS (₹)18.8232032.617.389.8—32.662.429.467.4
EPS adjusted (₹)—————89.884.632.662.329.367.4
0%0%0%5.4%10.1%1.9%—5.4%2.8%6%2.6%
Annual reportAnnual report for Mar 2016Annual report for Mar 2017Annual report for Mar 2018Annual report for Mar 2019Annual report for Mar 2020Annual report for Mar 2021Annual report for Mar 2022Annual report for Mar 2023Annual report for Mar 2024Annual report for Mar 2025Annual report for Mar 2026

₹ CrMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital333333
Reserves152203222260277317
1127303272108
3944325874102
Total equity & liabilities206278288353426530
58595960120144
CWIP1626465095
Investments333243576343
115180159190193248
Total assets206278288353426530

₹ CrMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
271632111735
-24-16-24-17-16-65
-1-1-1-1-130
Net cash flow2-17-700
Free cash flow2113-17-57-54
CFO / Operating profit %34.7%24.1%113.6%25.2%66.2%57.4%

Compounded sales growth

7 years
18%
5 years
14%
3 years
21%
1 year
36%

Compounded profit growth

7 years
11%
5 years
-6%
3 years
27%
1 year
130%

Stock price CAGR

10 years
—
5 years
0%
3 years
13%
1 year
107%

Return on equity

7 years
—
5 years
14%
3 years
11%
Last year
13%